Home › Funds › Trails Edge Capital Partners, LP › DSGN
Trails Edge Capital Partners, LP position in DSGN
DESIGN THERAPEUTICS INC · Health Care
Trails Edge Capital Partners, LP reported holding 2,001,282 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$29.0M, representing 4.60% of its reported portfolio and ranking #7 among its reported holdings. Trails Edge Capital Partners, LP has disclosed DSGN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's DSGN position evolved
Trails Edge Capital Partners, LP first disclosed a stake in DSGN in Q1 2026 at 852,013 shares (US$9.1M). The position peaked in Q2 2026 at 2,001,282 shares, worth US$29.0M. Across 2 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,001,282 shares valued at US$29.0M — an increase of 1,149,269 shares quarter over quarter.. Notable position changes include a 135% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 852.01K | $9.07M | New |
| Q2 2026 | 2.00M | $28.96M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- SR ONE CAPITAL MANAGEMENT, LP 6.53M sh · $94.44M · Q2 2026
- Logos Global Management LP 3.00M sh · $43.41M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M sh · $38.76M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K sh · $12.52M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 282.56K sh · $4.09M · Q2 2026
- KVP Capital Advisors, LP 185.00K sh · $2.68M · Q2 2026
- Elmind Capital, LP 107.90K sh · $1.56M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held DSGN?
Trails Edge Capital Partners, LP has disclosed DSGN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Trails Edge Capital Partners, LP's current position in DSGN?
As of Q2 2026, Trails Edge Capital Partners, LP holds 2.00M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $28.96M, representing 4.60% of its reported portfolio and ranking #7.
Has Trails Edge Capital Partners, LP been buying or selling DSGN?
In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP increased its position in DSGN. The position peaked in Q2 2026 at 2.00M shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BAKER BROS. ADVISORS LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.